2EFFERTH T,VOLM M.Pharmacogenetics for individualized canc er chemotherapy[J].Pharmacol Ther,2005,107:155-176.
3VIRGILE G,MANUELA D,FRANCOIS B,etal.MRP 1,-3 and 5 protein expression in non-small cell carcinomas and surgery after adjuvant chemotherapy[J].Lung Cancer,2005,49 (s2):S149.
4HIRANO T,KATO H,MAEDA M,etal.Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker[J].Int J Cancer,2005,117 (3):460-468.
5HITRE E,BUDAI B,AKLEFF V,et al.Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil[J].Pharma cogenet Genomics,2005,15 (10):723-730.
6INOUE K,TAKAO M,WATANABE F,et al.Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer-in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase[J].Lung Cancer,2005,49:47-54.
7XIE H G, PRASAD H C, KIM R B, et al. CYP2C9 allelic variants:ethnic distribution and functional significance [ J ]. Adv Drug Deliv Rev ,2002,54:1257-1270.
8RETTIE A E, JONES J P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics [ J ].Annu Rev Pharmacol Toxicol,2005 ,45:477-494.
9YASAR U, ELIASSON E, FORSLUND-BERGENGREN C, et al.The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro[J]. Eur J Clin Pharmacol,2001, 57 (10 ) :729-735.
10SHIMAMOTO J, IEIRI I, URAE A,et al. lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9 * 3 allele[J]. Eur J Clin Pharmacol,2000, 56(1) :65-68.
